Cao J, Sun Y, Ding X, Li S, Chen B, Lan T
School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Institute of Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Nan Fang Yi Ke Da Xue Xue Bao. 2024 Apr 20;44(4):652-659. doi: 10.12122/j.issn.1673-4254.2024.04.05.
To investigate the protective effect of arbutin against CCl-induced hepatic fibrosis in mice and explore the underlying mechanisms.
Twenty-four C57BL/6 mice were randomly divided into control group, model group, and low- and high-dose arbutin treatment (25 and 50 mg/kg, respectively) groups. Mouse models of liver fibrosis were established by intraperitoneal injection of CCl, and arbutin was administered daily gavage for 6 weeks. After the treatments, serum biochemical parameters of the mice were tested, and liver tissues were taken for HE staining, Sirius Red staining and immunohistochemical staining. RT-qPCR was used to detect the mRNA levels of , , , , and , and Western blotting was performed to detect α-SMA protein expression in the liver tissues. In the cell experiment, the effect of arbutin treatment for 24 h on THP-1 and RAW264.7 cell migration and recruitment was examined using Transwell migration assay and DAPI staining; The changes in protein levels of Akt, p65, Smad3, p-Akt, p-p65, p-Smad3 and α-SMA in arbutintreated LX-2 cells were detected with Western blotting.
Arbutin treatment significantly lowered serum alanine aminotransferase and aspartate aminotransferase levels, alleviated liver tissue damage and collagen deposition, and reduced macrophage infiltration and α-SMA protein expression in the liver of the mouse models ( < 0.05 or 0.001). Arbutin treatment also significantly reduced CCl-induced elevation of , , , , and mRNA levels in mice ( < 0.05). In the cell experiment, arbutin treatment obviously inhibited migration and recruitment of THP-1 and RAW264.7 cells and lowered the phosphorylation levels of Akt, p65 and Smad3 and the protein expression level of α-SMA in LX-2 cells.
Arbutin ameliorates liver inflammation and fibrosis in mice by inhibiting hepatic stellate cell activation via reducing macrophage recruitment and infiltration and suppressing activation of the Akt/NF-κB and Smad signaling pathways.
研究熊果苷对四氯化碳诱导的小鼠肝纤维化的保护作用,并探讨其潜在机制。
将24只C57BL/6小鼠随机分为对照组、模型组以及低剂量和高剂量熊果苷治疗组(分别为25和50mg/kg)。通过腹腔注射四氯化碳建立小鼠肝纤维化模型,每天经口灌胃给予熊果苷,持续6周。治疗后,检测小鼠血清生化指标,并取肝脏组织进行苏木精-伊红染色、天狼星红染色和免疫组化染色。采用逆转录-定量聚合酶链反应检测相关基因的mRNA水平,并用蛋白质免疫印迹法检测肝脏组织中α-平滑肌肌动蛋白的蛋白表达。在细胞实验中,采用Transwell迁移实验和4',6-二脒基-2-苯基吲哚染色检测熊果苷处理24小时对THP-1和RAW264.7细胞迁移和募集的影响;用蛋白质免疫印迹法检测熊果苷处理的LX-2细胞中Akt、p65、Smad3、p-Akt、p-p65、p-Smad3和α-平滑肌肌动蛋白蛋白水平的变化。
熊果苷治疗显著降低了血清谷丙转氨酶和谷草转氨酶水平,减轻了肝脏组织损伤和胶原沉积,减少了小鼠肝脏中的巨噬细胞浸润和α-平滑肌肌动蛋白蛋白表达(P<0.05或0.001)。熊果苷治疗还显著降低了四氯化碳诱导的小鼠相关基因mRNA水平的升高(P<0.05)。在细胞实验中,熊果苷治疗明显抑制了THP-1和RAW264.7细胞的迁移和募集,并降低了LX-2细胞中Akt、p65和Smad3的磷酸化水平以及α-平滑肌肌动蛋白的蛋白表达水平。
熊果苷通过减少巨噬细胞的募集和浸润以及抑制Akt/核因子κB和Smad信号通路的激活来抑制肝星状细胞活化,从而改善小鼠肝脏炎症和纤维化。